| Basics |
| Company: |
2seventy bio, Inc. Common Stock |
| IPO Date: |
November 3, 2021 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$134.65M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.38 | 3.69%
|
| Avg Daily Range (30 D): |
$0.09 | 3.36%
|
| Avg Daily Range (90 D): |
$0.12 | 3.49%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.64M |
| Avg Daily Volume (30 D): |
.24M |
| Avg Daily Volume (90 D): |
.27M |
| Trade Size |
| Avg Trade Size (Sh.): |
101 |
| Avg Trade Size (Sh.) (30 D): |
98 |
| Avg Trade Size (Sh.) (90 D): |
102 |
| Institutional Trades |
| Total Inst.Trades: |
681 |
| Avg Inst. Trade: |
$1.45M |
| Avg Inst. Trade (30 D): |
$5.49M |
| Avg Inst. Trade (90 D): |
$2.35M |
| Avg Inst. Trade Volume: |
.15M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.48M |
| Avg Closing Trade (30 D): |
$1.31M |
| Avg Closing Trade (90 D): |
$1.31M |
| Avg Closing Volume: |
131.3K |
|
|
|
|
| News |
Oct 9, 2024 @ 8:00 PM
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossm...
Source: Bronstein, Gewirtz & Grossman, Llc
|
Sep 27, 2024 @ 8:00 PM
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossm...
Source: Bronstein, Gewirtz & Grossman, Llc
|
May 16, 2024 @ 12:35 PM
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Labe...
Source: Zacks Equity Research
|
May 8, 2024 @ 12:15 PM
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Re...
Source: Zacks Equity Research
|
May 6, 2024 @ 4:43 PM
CRISPR (CRSP) to Report Q1 Earnings: What's in the...
Source: Zacks Equity Research
|
| Financials |
| |
TTM |
Q2 2024 |
Q1 2024 |
|
Basic EPS
|
$-.19
|
$.48
|
$-1.01
|
|
Diluted EPS
|
$-.19
|
$.45
|
$-1.01
|
|
Revenue
|
$ 13.53M
|
$ 8.97M
|
$ 12.44M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -9.93M
|
$ 24.88M
|
$ -52.67M
|
|
Operating Income / Loss
|
$ -13.94M
|
$ -27.07M
|
$ -51.15M
|
|
Cost of Revenue
|
$ M
|
$ M
|
$ M
|
|
Net Cash Flow
|
$ -51.95M
|
$ 55.27M
|
$ -19.66M
|
|
PE Ratio
|
|
|
|
|
